Melanoma
Peer to Peer
Evaluating Dermatology Apps for Patient Education
From the Journals
Topical imiquimod helps clear blurred lines in lentigo maligna excision
This topical agent reduces ambiguity when determining margins in Mohs surgery.
Conference Coverage
VIDEO: Gene test guides need for sentinel node biopsy in elderly melanoma patients
With T1-T2 tumors and a Class 1A test result, SLN positivity was 1.6% in patients 65 years and older.
From the Journals
Dermoscopy will help diagnose pediatric melanomas
Study adds to the knowledge base of these rare dermatologic lesions.
From the Journals
Melanoma incidence increased in older non-Hispanic whites
Skin cancer prevention efforts, which appear to have had an effect among young people, now need to target the older generation.
Conference Coverage
Be alert for BAP1 mutations in hereditary melanomas
MIAMI – They’re rare genetic mutations that can make melanoma more aggressive and lethal, as well as signal of a potentially elevated risk for...
Original Research
Mobile Medical Apps for Patient Education: A Graded Review of Available Dermatology Apps
The utilization of mobile applications (apps) as educational resources for patients highlights the need for an objective method of evaluating the...
From the Journals
Neoadjuvant dabrafenib and trametinib improves event-free survival in resectable melanoma
The phase 2 trial was closed early due to the difference in event-free survival favoring the neoadjuvant approach.
Feature
Supportive oncodermatology: Cancer advances spawn new subspecialty
Not too long ago at the Dana-Farber/Brigham and Women’s Cancer Center in Boston, a woman with widely metastatic melanoma, who had been planning...
Cold Iron Truth
Sentinel node biopsy: Who needs it?
If completion node dissection does not save lives, why do a sentinel node biopsy?
From the Journals
Desmoplastic melanoma yields to checkpoint inhibitors
Of 60 patients with desmoplastic melanoma treated with checkpoint inhibitors and followed for a median of 22 months, 42 had an objective response...